Aging and Thymosin Alpha-1.

This review paper examines the relationship between aging and Thymosin Alpha-1 (Tα1), a peptide hormone naturally produced by the thymus gland. The authors describe how age-related thymic involution leads to reduced T-cell production, chronic low-grade inflammation (inflammaging), and heightened vulnerability to age-related diseases — a phenomenon collectively termed immunosenescence. The paper outlines Tα1's proposed mechanisms of action, including stimulation of T-cell differentiation, enhancement of thymic output, and modulation of dendritic cells and macrophages. It also highlights Tα1's immunomodulatory, anti-inflammatory, and antioxidant properties. The authors review preclinical and clinical evidence suggesting Tα1 may improve vaccine responses in elderly populations and help counteract immunosenescence. Additionally, the paper discusses Refnot, a hybrid fusion drug combining Tα1 with tumor necrosis factor alpha (TNFα), which reportedly retains antitumor activity while exhibiting reduced toxicity compared to TNFα alone. The authors conclude that Tα1 holds therapeutic promise for age-related immune dysfunction but emphasize that long-term efficacy and safety data in geriatric populations remain limited and that further research is warranted. As a review, this paper synthesizes existing literature rather than presenting original experimental data.

Why this grade: This is a narrative review synthesizing preclinical and clinical literature; it does not present original trial data, so it is graded as review-level evidence.